000			05394nam a22004095i 4500
999			_c120891 _d120891 _x1
001			120891
003			ES-MaUEC
005			20230102114111.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			200617s2020 si | s |||| 0|eng d
020			_a9789811530135
024	7		_a10.1007/978-981-15-3013-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRS56 _b2020 EB
245	0	0	_aCommunicating about Risks and Safe Use of Medicines : _bReal Life and Applied Research _cedited by Priya Bahri
250			_a1st ed. 2020.
264		1	_aSingapore _bSpringer Singapore : _bImprint: Adis _c2020
300			_a1 recurso en línea (XXX, 504 páginas) _b32 ilustraciones, 30 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF _2rda
490	0		_aMedicine (Springer-11650)
505	0		_aForeword (Baruch Fischhoff) -- Preface: Guide for readers (Priya Bahri) -- Authors' biographical notes -- Overview of contents in chapters -- 1. A multilayered research framework for humanities and epidemiology of medicinal product risk communication (Priya Bahri) -- Part I: Medicines in real life as communication challenges. 2. Hormonal contraceptives - Communication for risk awareness and informed choice, or a public scare? (Barbara Mintzes, Teresa Alves, with a contribution from Priya Bahri) -- 3. COX-2 inhibitors - Communication of accumulating risk evidence and a product withdrawal (Amy Rogers, Kerr Grieve, Thomas M MacDonald, with a contribution from Sérgio Nishioka) -- 4. Isotretinoin - Communication for preventing birth defects and alerting of an uncertain risk of suicide (Ineke (HJMJ) Crijns) -- 5. Pandemic influenza vaccines - Communication of benefits, risks and uncertainties (Glen J Nowak, Emilie Karafillakis, Heidi Larson) -- Part II: Tackling the challenges - Methods for medicinal product risk communication research. 6. Ethical frameworks (Ghislaine van Thiel) -- 7. The cognitive and behavioural sciences (Sara Rubinelli, Nicola Diviani, Maddalena Fiordelli) -- 8. The social sciences (Brian Taylor, Anne Moorhead) -- 9. Rhetoric and science & technology studies (Mathias Møllebæk) -- 10. Media science and practice (Glen J Nowak, Michael A Cacciatore) -- 11. Social media research (Nabarun Dasgupta, Carly Winokur, Carrie E Pierce) -- 12. Design science with a focus on user-centred evaluation of written information (Jörg Fuchs) -- 13. Dissemination & implementation science (Elaine Morrato, Meredith Smith) -- 14. Pharmacoepidemiology (Bert (HGM) Leufkens) -- 15. Legal frameworks (Burkhard Sträter) -- 16. From passive to active - Patients as contributors to medicinal product risk communication research (François Houÿez) -- Afterword: The dimension of communicating medicine risks in low- and middle-income countries (Nilima A Kshirsagar).
520	3		_aAt the core of this book lies the question how to approach medicines, risks and communication as a researcher - or anybody planning and evaluating a communication intervention, or wanting to understand communication events in private and the media. With a view to tackle current shortcomings of communication systems and processes for improved implementation, patient satisfaction and health outcomes, a multilayered approach is presented. This combines multiple data types and methods to obtain a wider and deeper understanding of the major parties and their interactions, as well as the healthcare, social and political contexts of information flows, how they interfere and which impact they have. Illustrated with real life experiences of safety concerns with medicines, worldwide active experts discuss the methods and contributions their disciplines can offer. With considerations on terminologies, tabulated overviews on communication types and outcomes, a patient-centred vision and plain language for non-medical readers, the book creates a platform for multidisciplinary collaborations amongst researchers as well as practitioners from communications, healthcare, the social sciences and pharmacovigilance. Importantly, it advocates for an active role of patients and highlights the achievements and aspirations of patient organisations. Finally, the book suggests establishing an inclusive discipline of humanities and epidemiology of medicinal product risk communication to realise full research potential. The authors are driven by the curiosity for communication as the most human behaviour, and as good health is amongst the basic human needs, medicinal product risk communication is an exciting research field of high global relevance.
988			_aSpringer_Medicine_2020
650		7	_aComunicación en medicina _2embne _9154635
650		7	_aDrogas _2embne _9139235
700	1		_aBahri, Priya. _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729
776	0	8	_iPrinted edition: _z9789811530128
776	0	8	_iPrinted edition: _z9789811530142
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-15-3013-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b09/2020 _dz _eo _zSI